Form 4: Director Scott Morrison Reports TARS Stock Transactions

Director Scott Morrison of Tarsus Pharmaceuticals, Inc. (TARS) reported transactions involving the acquisition of common stock through the settlement of Restricted Stock Units.

Summary

• Scott W. Morrison, a Director at Tarsus Pharmaceuticals, Inc. (TARS), reported a transaction on June 12, 2026.
• This transaction involved the acquisition of 2,954 shares of common stock through the settlement of vested Restricted Stock Units (RSUs).
• Following this transaction, Morrison directly owns 7,638 shares of common stock.
• Additionally, Morrison beneficially owns 6,016 shares indirectly through the Morrison-Minton Family 2004 Trust, of which he is a trustee and he and his spouse are beneficiaries.
• The RSUs were granted on June 12, 2025, in connection with his service as a non-employee director and vested on the one-year anniversary of the grant date, subject to continued service.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral filing, as it represents a routine settlement of equity awards for a director rather than a new investment or divestment decision.

Positives

• Director Scott Morrison's acquisition of shares through RSU settlement indicates continued commitment and alignment with the company's performance.
• The vesting of RSUs suggests the company is meeting its performance or service obligations to its directors.

Future Outlook

No specific forward-looking statements or guidance were provided in this Form 4 filing.

Industry Context

StockSavvy.ai notes that Form 4 filings are standard disclosures for insider transactions, providing transparency into the holdings and activities of company directors and officers. This filing specifically details the conversion of equity awards into actual shares for a director.

Stakeholder Impact

• Shareholders: Increased transparency into director's holdings and potential alignment of interests.
• Employees: Indirectly, the vesting of RSUs can be seen as a component of executive compensation and retention strategies.

Key Dates

Keywords

Tarsus Pharmaceuticals, TARS, Form 4, SEC Filing, Director Transaction, Restricted Stock Units, RSU Settlement, Beneficial Ownership, Insider Trading